Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique; Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam, The Netherlands; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Rossello 132, 08036 Barcelona, Spain.
Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, United States.
Pulmonology. 2018 Mar-Apr;24(2):73-85. doi: 10.1016/j.rppnen.2017.12.002. Epub 2018 Feb 14.
The goals of the End TB strategy, which aims to achieve a 90% reduction in tuberculosis (TB) incidence and a 95% reduction in TB mortality by 2035, will not be achieved without new tools to fight TB. These include improved point of care (POC) diagnostic tests that are meant to be delivered at the most decentralised levels of care where the patients make the initial contact with the health system, as well as within the community. These tests should be able to be performed on an easily accessible sample and provide results in a timely manner, allowing a quick treatment turnaround time of a few minutes or hours (in a single clinical encounter), hence avoiding patient loss-to-follow-up. There have been exciting developments in recent years, including the WHO endorsement of Xpert MTB/RIF, Xpert MTB/RIF Ultra, loop-mediated isothermal amplification (TB-LAMP) and lateral flow lipoarabinomannan (LAM). However, these tests have limitations that must be overcome before they can be optimally applied at the POC. Furthermore, worrying short- to medium-term gaps exist in the POC diagnostic test development pipeline. Thus, not only is better implementation of existing tools and algorithms needed, but new research is required to develop new POC tests that allow the TB community to truly make an impact and find the "missed TB cases".
如果没有新的工具来抗击结核病,实现 2035 年结核病(TB)发病率降低 90%和死亡率降低 95%的终结结核病战略目标将无法实现。这些新工具包括改进的即时护理(POC)诊断测试,这些测试旨在在最分散的护理水平上提供,即在患者与卫生系统首次接触的地方,以及在社区内提供。这些测试应该能够在易于获取的样本上进行,并及时提供结果,从而实现几分钟或几个小时的快速治疗周转时间(在单次临床就诊中),从而避免患者失访。近年来,出现了一些令人兴奋的进展,包括世卫组织对 Xpert MTB/RIF、Xpert MTB/RIF Ultra、环介导等温扩增(TB-LAMP)和侧向流脂质阿拉伯甘露聚糖(LAM)的认可。然而,这些测试存在必须克服的局限性,然后才能在 POC 上最佳应用。此外,POC 诊断测试开发管道中存在令人担忧的短期至中期差距。因此,不仅需要更好地实施现有工具和算法,还需要开展新的研究来开发新的 POC 测试,以使结核病界真正产生影响并发现“漏诊的结核病病例”。